Search
Fangsheng Pharmaceutical Secures Drug Approval for Innovative Chinese Medicine Yangxue Qufeng Zhitong Granules
2025-06-09 /
Read about 0 minute
Author：小编
On June 9, Fangsheng Pharmaceutical proudly announced that its wholly-owned subsidiary, Jianmeng Pharmaceutical, had been granted the Drug Registration Certificate by the National Medical Products Administration. This significant milestone marks the approval of Yangxue Qufeng Zhitong Granules, an innovative traditional Chinese medicine (TCM) developed in-house, for production. Composed primarily of Astragalus and Angelica sinensis, this drug is specifically designed for the treatment of recurrent tension-type headaches. Having successfully completed both Phase II and Phase III clinical trials, Yangxue Qufeng Zhitong Granules has demonstrated robust safety and efficacy profiles.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
